非布司他（feburic）中文的说明书

Febuxostat (feburic) instructions

All names: febuxostat, febuxostat, feburic, febuxostat, uloric, zurig

Indications: For the treatment of chronic hyperuricemia (gout).

Dosage: The starting oral dose of febuxostat is 40 mg once daily. Since the drug-enzyme complex formed by febuxostat and xanthine oxidase is extremely stable and its uric acid-lowering effect is stronger than that of allopurinol, blood uric acid can be rechecked after 2 weeks of taking it. If the serum uric acid level is still not less than 360 umol/L after 2 weeks, it is recommended to increase the dose to 80 mg once daily. It is recommended to take the medicine for at least 6 months to prevent acute attacks of gout. If gout occurs during treatment with this drug, there is no need to discontinue the drug. An increase in the frequency of gout attacks often occurs during the early stages of taking febuxostat. This is because blood uric acid concentration decreases, leading to mobilization of urate deposited in tissues. To prevent gout attacks during the initial stages of treatment, it is recommended to take nonsteroidal anti-inflammatory drugs or colchicine at the same time.

Adverse reactions: Abnormal liver function is also one of the common adverse reactions of febuxostat, which manifests as fatigue, loss of appetite, jaundice, diarrhea, etc. If the above conditions occur during medication, liver function should be checked. After diagnosis, the medication should be discontinued, and liver-protective treatment should be performed if necessary.

Things to note:

Gout attacks: After starting treatment with this product, an increase in gout attacks may be observed. This is caused by changing serum uric acid levels that reduce the activity of deposited urate. To prevent gout attacks while administering this product, concomitant administration of a nonsteroidal anti-inflammatory drug or colchicine is recommended.

Cardiovascular disorders: In randomized controlled trials, patients taking febuxostat (feburic) were more likely to have cardiovascular thrombotic events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) than patients taking allopurinol. The reasons for this are not yet clear. Monitor for signs and symptoms of myocardial infarction (MI) and stroke.